United Therapeutics Corporation's stock experienced a significant boost following a favorable court ruling.
Shares of United Therapeutics Corporation (NASDAQ:UTHR) went up yesterday by an impressive 12.55%, closing at $541.89. This surge was primarily driven by a recent court decision that favored the company's patent claims against competitor Liquidia Corporation.
Advertisement
United Therapeutics Corporation
UTHR.US
UTHR.US
United Therapeutics Corporation
WealthAwesomeMarket cap
$23.01B
P/E
19.2x
52W high
$609.35
52W low
$409.07
1W change
+10.47%
Beta
0.49
Analyst Price Targets
Based on 15 analysts covering UTHR · as of Oct 5, 2026
Wall Street analysts forecast UTHR stock price to rise 20.1% over the next 12 months.
Consensus
Buy4.13 / 5.00
Avg. Target
C$644.36
+20.1% Upside
Current Price
C$536.40
Last close
Analyst Breakdown (15 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on UTHR's historical volatility
30-Day Vol
47.6%
Annualized
90-Day Vol
32.4%
Annualized
Trend (90d)
-8.3%
Annualized drift
90d Mean
C$520.80
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$531.15 | C$450.73 – C$625.91 |
| 60 trading days | C$525.95 | C$416.98 – C$663.39 |
| 90 trading days | C$520.80 | C$391.91 – C$692.08 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should monitor United Therapeutics closely, as the recent court ruling could lead to reduced competition and potential financial benefits, even amidst mixed earnings expectations.
12.55% Surge
United Therapeutics' stock jumped 12.55% yesterday, marking a significant recovery from a prior 6.1% loss over the past month.
Bull case
The favorable court ruling may reduce competition for United Therapeutics' key products, which could boost future revenues and profits. If the company successfully claims damages from Liquidia, it might also enhance its financial stability.
Bear case
Despite the positive news, analysts have lowered their earnings estimates, indicating potential challenges ahead. The company's revenue is expected to decline slightly, raising concerns about its long-term growth prospects.
Advertisement
Court Ruling Boosts Stock
The significant increase in United Therapeutics' stock price was largely due to a ruling from a Delaware court that found Liquidia's inhaled treprostinil product infringed on United Therapeutics' patents. This decision could limit Liquidia's ability to compete in the pulmonary hypertension market, benefiting United Therapeutics' Tyvaso and Tyvaso DPI products.
Market Reactions and Future Outlook
While the immediate market reaction to the court ruling was positive, analysts caution that the company faces challenges ahead. The consensus estimate for United Therapeutics' upcoming quarterly earnings has been revised downward, reflecting concerns about potential revenue declines. Investors should keep an eye on how these factors will influence the stock's performance in the coming weeks.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
